2,3-Dinor 11B-Prostagladin F2 (23BPT) from US at Chughtai Lab

2,3-Dinor 11B-Prostagladin F2 (23BPT) from US at Chughtai Lab

The 2,3-Dinor 11B-Prostagladin F2 (23BPT) from US test offered at Chughtai Lab is a highly specialized, state-of-the-art laboratory investigation designed to measure the urinary levels of 2,3-dinor-11-beta-prostaglandin F2 alpha (2,3-dinor-11B-PGF2a). This compound is a primary, stable metabolite of prostaglandin D2 (PGD2), which is a major lipid mediator produced and released by activated mast cells. Mast cells are key components of the immune system, residing in vascularized tissues, mucosal surfaces, and epithelial barriers. When these cells are triggered by immunological or non-immunological stimuli, they undergo degranulation, releasing a cascade of preformed and newly synthesized chemical mediators. Among these, PGD2 plays a critical role in mediating bronchoconstriction, vasodilation, and inflammatory cell recruitment.

Because PGD2 is rapidly metabolized in the human body and has an extremely short half-life in blood, direct measurement of plasma PGD2 is clinically impractical and highly unreliable. Instead, measuring its stable urinary metabolite, 2,3-dinor-11B-PGF2a, provides an integrated, highly accurate assessment of systemic prostaglandin D2 production over time. This makes the 2,3-Dinor 11B-Prostagladin F2 (23BPT) from US test an invaluable clinical biomarker for diagnosing and monitoring complex mast cell activation disorders, including Mast Cell Activation Syndrome (MCAS), systemic mastocytosis, and severe, unexplained anaphylaxis. Chughtai Lab, Pakistan’s premier diagnostic network, facilitates this advanced test by partnering with leading, accredited reference laboratories in the United States, ensuring that patients in Lahore, Karachi, Islamabad, and across the country have access to world-class diagnostic precision.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the utmost accuracy of the 2,3-Dinor 11B-Prostagladin F2 (23BPT) from US test, strict adherence to patient preparation guidelines is essential. Because this test measures prostaglandin metabolites, any medication that interferes with prostaglandin synthesis can cause false-negative results. Patients must follow these preparation steps carefully:

• Discontinue Prostaglandin Inhibitors: Under the guidance of your prescribing physician, discontinue all nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, ibuprofen, naproxen, diclofenac, meloxicam, and celecoxib for at least 72 hours (ideally 5 days) prior to and during the collection period. These medications block the cyclooxygenase (COX) enzymes, artificially suppressing prostaglandin levels.
• Avoid Glucocorticoids and Mast Cell Stabilizers: If clinically permissible, consult your physician about temporarily stopping medications like oral corticosteroids, cromolyn sodium, or ketotifen, as these can suppress mast cell activity and lower metabolite levels.
• Maintain Normal Hydration: Drink a normal, moderate amount of water during the collection period. Avoid extreme overhydration, which can excessively dilute the urine, or severe dehydration, which can alter creatinine normalization.
• Avoid Vigorous Physical Exertion: Refrain from intense exercise, heavy lifting, or extreme physical stress for 24 hours before and during the collection, as physical stress can naturally trigger mast cell degranulation and cause transient elevations.
• Follow Collection Instructions: Obtain the specialized 24-hour urine collection container and preservative (if required) from Chughtai Lab prior to starting the test.

During the Procedure

The 2,3-Dinor 11B-Prostagladin F2 (23BPT) from US test is typically performed on a 24-hour urine specimen, though random urine collection may be utilized in specific acute clinical scenarios. The 24-hour collection process is conducted as follows:

• Day 1 – Start of Collection: Upon waking, urinate into the toilet to empty your bladder completely. Do not save this first urine. Record this exact time as the start time (e.g., 8:00 AM).
• 24-Hour Collection Period: Collect every drop of urine voided during the next 24 hours into the specialized container provided by Chughtai Lab. This includes any urine voided during the night.
• Temperature Control: Keep the collection container refrigerated or stored in a cooler with ice packs throughout the entire 24-hour period. Heat causes rapid degradation of the prostaglandin metabolite, which can invalidate the test.
• Day 2 – Completion of Collection: Exactly 24 hours after the start time, wake up and urinate into the container one final time (e.g., at 8:00 AM). This completes the collection process.
• Specimen Transport: Securely seal the container, label it with your full name, date of birth, and the exact start and end times of the collection. Deliver the specimen immediately to the nearest Chughtai Lab collection center while keeping it cold during transport.
• International Shipping Process: Once received, Chughtai Lab’s specialized laboratory team will measure the total volume, aliquot the specimen, and freeze it. The sample is then shipped to a premier reference laboratory in the United States under strict, temperature-controlled cold chain logistics to preserve specimen integrity.

When is a 2,3-Dinor 11B-Prostagladin F2 (23BPT) from US Performed?

Suspected Mast Cell Activation Syndrome (MCAS)

Physicians request this test when a patient exhibits chronic, episodic symptoms across multiple organ systems that suggest Mast Cell Activation Syndrome (MCAS). These symptoms include recurrent abdominal pain, cramping, chronic diarrhea, flushing, hives (urticaria), itching, rapid heart rate (tachycardia), lightheadedness, and cognitive difficulties (brain fog). Because MCAS involves episodic mediator release, measuring urinary 2,3-dinor-11B-PGF2a during or immediately following a symptomatic flare helps confirm that mast cell degranulation is the underlying driver of the patient’s multi-system symptoms.

Evaluation of Systemic Mastocytosis

Systemic Mastocytosis is a rare clonal disorder characterized by the abnormal proliferation and accumulation of neoplastic mast cells in various organs, including the skin, bone marrow, liver, spleen, and gastrointestinal tract. While a bone marrow biopsy and serum tryptase levels are primary diagnostic tools, urinary 2,3-dinor-11B-PGF2a serves as an essential complementary biomarker. It helps clinicians assess the total burden of mast cell activity, differentiate between subtypes of mastocytosis, and identify patients who produce high levels of prostaglandins, which can guide targeted therapeutic decisions.

Investigation of Unexplained Recurrent Anaphylaxis

Anaphylaxis is a severe, life-threatening systemic allergic reaction that requires immediate medical intervention. In many cases, patients experience recurrent episodes of anaphylaxis with no identifiable trigger, a condition known as idiopathic anaphylaxis. When standard allergy testing fails to yield answers, physicians order the 2,3-Dinor 11B-Prostagladin F2 (23BPT) from US test to determine if an underlying mast cell degranulation disorder is responsible for these sudden, severe drops in blood pressure, airway constriction, and cardiovascular compromise.

Monitoring Therapeutic Response in Mast Cell Disorders

For patients already diagnosed with mast cell activation disorders or systemic mastocytosis, this test is an invaluable tool for monitoring the effectiveness of medical therapy. Clinicians use baseline urinary levels of 2,3-dinor-11B-PGF2a and compare them with post-treatment levels. A significant reduction in the excretion of this metabolite indicates that therapies such as mast cell stabilizers (e.g., cromolyn sodium), H1 and H2 antihistamines, leukotriene inhibitors, or cytoreductive therapies are successfully controlling mast cell mediator release and reducing systemic inflammation.

Differential Diagnosis of Severe Flushing and Gastrointestinal Distress

Episodic flushing and severe gastrointestinal symptoms can be caused by a variety of medical conditions, including carcinoid syndrome, pheochromocytoma, VIPoma, autonomic dysfunction, or severe irritable bowel syndrome (IBS). The 2,3-Dinor 11B-Prostagladin F2 (23BPT) from US test helps clinicians narrow down the differential diagnosis. Elevated levels of this specific prostaglandin metabolite strongly point toward a mast cell-mediated process, allowing physicians to rule out other endocrine or neurological disorders and initiate the correct, targeted treatment plan.

What Does a 2,3-Dinor 11B-Prostagladin F2 (23BPT) from US Detect?

The 2,3-Dinor 11B-Prostagladin F2 (23BPT) from US test is highly sensitive and detects subtle variations in prostaglandin production. Specifically, the test can detect and help evaluate the following clinical findings:

• Elevated urinary levels indicating active, systemic mast cell degranulation.
• Normal baseline levels during asymptomatic periods in patients with episodic Mast Cell Activation Syndrome.
• Markedly elevated levels characteristic of systemic mastocytosis and clonal mast cell disorders.
• Suppressed metabolite levels resulting from recent nonsteroidal anti-inflammatory drug (NSAID) or aspirin therapy.
• Elevated levels associated with severe, acute IgE-mediated allergic reactions.
• Fluctuations in prostaglandin production that correlate with the severity of clinical symptoms.
• Normal levels that help rule out prostaglandin-mediated pathways in patients with non-mast cell flushing.
• Elevated levels in patients with Monoclonal Mast Cell Activation Syndrome (MMAS).
• Decreased levels following successful clinical intervention with mast cell stabilizers or tyrosine kinase inhibitors.
• Elevated levels during acute asthma exacerbations with significant mast cell involvement.
• Elevated levels associated with severe, refractory atopic dermatitis and chronic urticaria.
• False-negative results caused by improper cold chain maintenance or thermal degradation of the specimen.
• False-positive results due to intense physical exertion or extreme physiological stress prior to collection.
• Elevated levels in patients with clonal hematological non-mast cell lineage diseases (AHNMD).
• Normal levels in patients with functional gastrointestinal disorders mimicking MCAS.
• Elevated levels associated with drug-induced hypersensitivity syndrome (DIHS/DRESS).
• Elevated levels in patients with interstitial cystitis or bladder pain syndrome involving bladder mast cells.
• Normal levels in patients experiencing panic disorder or autonomic flushing mimicking anaphylaxis.
• Elevated levels in patients with systemic sclerosis or other fibrotic disorders where mast cells play a pathogenic role.
• Elevated levels in patients with severe allergic bronchopulmonary aspergillosis (ABPA).
• Normal levels confirming adequate therapeutic control and stabilization of mast cell degranulation.

Turnaround Time and Report Access at Chughtai Lab

Because the 2,3-Dinor 11B-Prostagladin F2 (23BPT) from US test is a highly specialized investigation, the specimen is processed using advanced liquid chromatography-tandem mass spectrometry (LC-MS/MS) at a premier reference laboratory in the United States. Due to the international shipping, customs clearance, and complex analytical procedures involved, the turnaround time for this test is typically 10 to 14 business days. Chughtai Lab ensures that the specimen is kept continuously frozen during transit to maintain absolute diagnostic accuracy. Once the results are finalized by the US reference laboratory, they are uploaded directly to the Chughtai Lab database. Patients and referring physicians can easily access the reports online through the official Chughtai Lab website, the Chughtai Lab mobile application, or via their dedicated WhatsApp service, ensuring a seamless and convenient experience.

2,3-Dinor 11B-Prostagladin F2 (23BPT) from US Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
2,3-Dinor-11B-PGF2a Level	Within established reference range (typically < 1000 pg/mg creatinine, depending on age and reference lab standards)	Elevated levels (> 1000 pg/mg creatinine), indicating active mast cell degranulation, MCAS, or systemic mastocytosis.
Creatinine Concentration	Normal urinary creatinine excretion, used to normalize the metabolite concentration against urine dilution	Abnormally low or high creatinine levels, indicating highly dilute or concentrated urine, requiring cautious clinical interpretation.
NSAID Interference	No recent NSAID or aspirin use, ensuring accurate baseline prostaglandin levels	Suppressed metabolite levels due to recent use of COX inhibitors, leading to potential false-negative results.
Specimen Temperature	Specimen kept continuously frozen or refrigerated, preserving metabolite integrity	Specimen left at room temperature, leading to thermal degradation of the prostaglandin metabolite and falsely low readings.
Collection Duration	Complete and accurate 24-hour urine collection	Incomplete collection (under-collection or over-collection), leading to inaccurate total metabolite calculations.
Clinical State During Collection	Baseline state (asymptomatic period) with normal or slightly elevated levels	Symptomatic flare or post-anaphylaxis period with significantly elevated levels.
Concomitant Mast Cell Mediators	Normal levels of other mast cell-derived mediators	Elevated levels of urinary N-methylhistamine or serum tryptase, confirming multi-mediator mast cell activation.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for 2,3-Dinor 11B-Prostagladin F2 (23BPT) from US?

• Experienced Healthcare Professionals: Chughtai Lab is staffed by highly qualified pathologists, technologists, and clinical scientists dedicated to diagnostic excellence.
• International Reference Partnerships: Chughtai Lab collaborates with top-tier, accredited laboratories in the United States to offer specialized tests that are otherwise unavailable locally.
• Strict Cold Chain Management: The lab maintains a rigorous, temperature-controlled cold chain to ensure specimens remain frozen and biologically stable during international transit.
• Convenient Sample Collection: With an extensive network of collection centers across Lahore, Karachi, Islamabad, and other major cities, patients can easily submit their samples.
• Patient-Focused Care: Chughtai Lab prioritize patient comfort, safety, and clear communication throughout the testing process.
• Digital Report Access: Patients can conveniently download their highly detailed diagnostic reports via the Chughtai Lab website, mobile app, or WhatsApp.
• Comprehensive Diagnostic Menu: Chughtai Lab offers a full suite of complementary tests, including serum tryptase and urinary histamine, for a complete mast cell evaluation.
• Commitment to Quality: Adhering to international quality control standards, Chughtai Lab ensures reliable, reproducible, and clinically actionable results for every patient.